BrightEdge
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO
Geographical Focus
United States, Canada, Europe, Asia
Industries Focus
- Healthcare
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Health Services
- Medical Research
- Clinical Trials
- Oncology
- Health Technology
- Public Health
- Health Policy
- Health Equity
- Patient Support
Investment Size:
500,000 to 2,500,000 USD
Investor Details Founded: 2019
BrightEdge is the innovation and impact investment arm of the American Cancer Society (ACS), dedicated to accelerating the commercialization of patient-centric innovations across the cancer continuum. By investing in early-stage companies developing cutting-edge cancer-focused therapeutics, diagnostics, devices, and technologies, BrightEdge aims to reduce cancer mortality, end pain and suffering, and advance health equity.
Established in 2019 with an initial $25 million investment from ACS, the American Cancer Society Impact Venture Fund (AIVF) has grown significantly, reaching $80.3 million by the close of 2023. This growth reflects ACS’s deepened and unwavering commitment to supporting impactful innovations, alongside the support from generous donors in the BrightEdge Founders Circle. The AIVF portfolio serves as a dynamic hub where cutting-edge companies develop breakthroughs across the cancer care continuum, from early detection to treatment to survivorship.
BrightEdge operates under a charitable fund model that invests in for-profit companies developing novel cancer-focused therapies and technologies. The fund relies on the expertise of the Society’s medical and science professionals to evaluate the mission value of its investments. The fund’s goal is to accelerate delivery of promising cancer-related solutions through capital investment, market awareness, and a shared commitment to eradicate cancer.
Requirements
- Early-stage companies developing cancer-focused therapeutics, diagnostics, devices, and technologies
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Castle Biosciences
- Immunitas Therapeutics
- TailorMed
Claim this Investor
Are you an official representative of BrightEdge?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim